Equity Securities, Stock Purchase Agreement, Par Value Per Share

No definition available.

Name:	rnac_EquitySecuritiesStockPurchaseAgreementParValuePerShare
Namespace Prefix:	rnac_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Equity Securities, Stock Purchase Agreement, Purchase Price Per Share

+ References

No definition available.

+ Details

Name:	rnac_EquitySecuritiesStockPurchaseAgreementPurchasePricePerShare
Namespace Prefix:	rnac_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Equity Securities, Stock Purchase Agreement, Shares Purchased

+ References

No definition available.

+ Details

Name:	rnac_EquitySecuritiesStockPurchaseAgreementSharesPurchased
Namespace Prefix:	rnac_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

License And Option Agreement, Milestone Payments

+ References

No definition available.

+ Details

Name:	rnac_LicenseAndOptionAgreementMilestonePayments
Namespace Prefix:	rnac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 321
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479536/321-10-50-3

+ Details

Name:	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=rnac_CyrusBiotechnologyIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=rnac_SeriesBPreferredStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Cyrus Biotechnology, Inc. (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Sep. 07, 2021	Sep. 30, 2021	Sep. 30, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity securities without readily determinable fair value, amount			$ 2,000	$ 2,000
Cyrus Biotechnology, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment		$ 1,500,000
Equity securities, stock purchase agreement, shares purchased (in shares)	2,326,934
Equity securities without readily determinable fair value, amount	$ 2,000		$ 2,000
Cyrus Biotechnology, Inc. \| Series B Preferred Stock Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity securities, stock purchase agreement, par value per share (in dollars per share)	$ 0.0001
Equity securities, stock purchase agreement, purchase price per share (in dollars per share)	$ 0.8595